Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NFκB signaling, and synergizes with an ERK inhibitor

Cancer Biology and Therapy

Volumn 13, Issue 6, 2012, Pages 349-357

  Yang, Fan ^a   Jove, Veronica ^a   Chang, Shirley ^a   Hedvat, Michael ^a   Liu, Lucy ^a   Buettner, Ralf ^a   Tian, Yan ^a   Scuto, Anna ^a   Wen, Wei ^a   Yip, M L Richard ^a   Van Meter, Timothy E ^b   Yen, Yun ^a   Jove, Richard ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AKT; Apoptosis; Bortezomib; Brain tumor; Erk inhibitor; Medulloblastoma; NF B; Proliferation

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (2 AMINOETHYL) 5 [(4 ETHORYPHENYL)METHYLENE] 2,4 THIAZOLIDINEDIONE; BORTEZOMIB; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAD; PROTEIN BAK; PROTEIN KINASE B; TRICIRIBINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINO ACID CHLOROMETHYL KETONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BORONIC ACIDS; CASPASE 3; CASPASE 9; CEREBELLAR NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOCHROMES C; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEDULLOBLASTOMA; NF-KAPPA B; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 84860255301     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.6.19239     Document Type: Article

References (43)

1. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 2008; 14:971-6; PMID:18281528; http://dx.doi.org/10.1158/1078-0432.CCR-07-2072.
2. Dhall G. Medulloblastoma. J Child Neurol 2009; 24:1418-30; PMID:19841429; http://dx.doi. org/10.1177/0883073809341668.
3. McNeil DE, Coté TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002; 39:190-4; PMID:12210449; http://dx.doi.org/10.1002/mpo.10121.
4. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic betacatenin mutations. Cancer Res 1998; 58:896-9; PMID:9500446.
5. Hartmann W, Digon-Söntgerath B, Koch A, Waha A, Endl E, Dani I, et al. Phosphatidylinositol-3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 2006; 12:3019-27; PMID:16707597; http://dx.doi.org/10. 1158/1078-0432.CCR-05-2187.
6. Włodarski P, Grajkowska W, Łojek M, Rainko K, Józwiak J. Activation of Akt and Erk pathways in medulloblastoma. Folia Neuropathol 2006; 44:214-20; PMID:17039417.
7. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105; PMID:14964307; http://dx.doi.org/10.1038/nrc1275.
8. Schaefer LK, Ren Z, Fuller GN, Schaefer TS. Constitutive activation of Stat3alpha in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002; 21:2058-65; PMID:11960378; http://dx.doi.org/10.1038/sj.onc.1205263.
9. Wlodarski PK, Boszczyk A, Grajkowska W, Roszkowski M, Jozwiak J. Implication of active Erk in the classic type of human medulloblastoma. Folia Neuropathol 2008; 46:117-22; PMID:18587705.
10. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143-52; PMID:11544480; http://dx.doi. org/10.1038/ng731.
11. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16:433-43; PMID:11960320; http://dx.doi.org/10. 1038/sj.leu.2402417.
12. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Pat Anticancer Drug Discov 2006; 1:397-403; PMID:18221049; http://dx.doi.org/10.2174/157489206778776925.
13. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 2008; 8:1053-72; PMID:18588451; http://dx.doi.org/10.1586/ 14737140.8.7.1053.
14. Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer 2007; 43:1125-33; PMID:17379504; http://dx.doi.org/10.1016/j.ejca.2007.01.038.
15. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-60; PMID:15122206; http://dx.doi.org/10.1038/nrc1361.
16. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5:18; PMID:15929791; http://dx.doi.org/10.1186/1475-2867-5-18.
17. Van Waes C. Nuclear factorkappaB in development, prevention and therapy of cancer. Clin Cancer Res 2007; 13:1076-82; PMID:17317814; http://dx.doi. org/10.1158/1078-0432.CCR-06-2221.
18. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H. Inhibition of nuclear factor kappaB signaling reduces growth in medulloblastoma in vivo. BMC Cancer 2011; 11:136; PMID:21492457; http://dx.doi. org/10.1186/1471-2407-11-136.
19. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappaB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-28; PMID:11350913.
20. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5:417-21; PMID:15144949; http://dx.doi.org/10.1016/S1535- 6108(04)00120-5.
21. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1beta-converting enzyme. J Biol Chem 1994; 269:30761-4; PMID:7983002.
22. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998; 273:33533-9; PMID:9837934; http://dx.doi. org/10.1074/jbc.273.50.33533.
23. Meng XW, Lee SH, Kaufmann SH. Apoptosis in the treatment of cancer: a promise kept? Curr Opin Cell Biol 2006; 18:668-76; PMID:17049222; http://dx.doi.org/10.1016/j.ceb.2006.10.008.
24. Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci 2009; 100:1374-81; PMID:19459846; http://dx.doi.org/10.1111/j.1349-7006.2009.01196.x.
25. Lu Z, Hunter T. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors. Cell Cycle 2010; 9:2342-52; PMID:20519948; http://dx.doi.org/10.4161/cc.9.12.11988.
26. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305:626- 9; PMID:15286356; http://dx.doi.org/10.1126/science. 1099320.
27. Yonezawa K, Yoshino KI, Tokunaga C, Hara K. Kinase activities associated with mTOR. Curr Top Microbiol Immunol 2004; 279:271-82; PMID:14560963; http://dx.doi.org/10.1007/978-3-642-18930-2-16.
28. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10:13-29; PMID:17303468; http://dx.doi.org/10.1016/j. drup.2007.01.003.
29. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422.
30. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 2008; 7:3519-26; PMID:19001435; http://dx.doi.org/10.1158/1535-7163.MCT-08- 0138.
31. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 1:530-43.
32. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84:5034-7; PMID:3037531; http://dx.doi.org/10.1073/ pnas.84.14.5034.
33. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol-3′-kinase/AKT pathways. Oncogene 2005; 24:7443-54; PMID:16288291; http://dx.doi. org/10.1038/sj.onc.1209091.
34. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-83; PMID:16169463; http://dx.doi.org/10.1016/j.ccr.2005.08.008.
35. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-88; PMID:16883305; http://dx.doi.org/10.1038/nrd2062.
36. Prasad S, Ravindran J, Aggarwal BB. NFkappaB and cancer: how intimate is this relationship. Mol Cell Biochem 2010; 336:25-37; PMID:19823771; http://dx.doi.org/10.1007/s11010-009-0267-2.
37. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NFkappaB by the Akt/PKB kinase. Curr Biol 1999; 9:601-4; PMID:10359702; http://dx.doi.org/10. 1016/S0960-9822(99)80265-6.
38. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome. Biochim Biophys Acta 2008; 1786:153-77.
39. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269:682-5; PMID:7624798; http://dx.doi. org/10.1126/science.7624798.
40. Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma. Leuk Res 2007; 31:721-3; PMID:16890285; http://dx.doi. org/10.1016/j.leukres.2006.06.019.
41. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006; 79:141-52; PMID:17940624.
42. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK and NFkappaB. J Biol Chem 2008; 283:1545-52; PMID:17991734; http://dx.doi.org/10.1074/jbc.M707931200.
43. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001; 20:2499-513; PMID:11420660; http://dx.doi. org/10.1038/sj.onc.1204349.